MetaCap

Nautilus Biotechnology Inc. (NAUT)

NASDAQ: NAUTIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

2.12-0.05 (-2.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NAUT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$270.03M
EPS (TTM)
-$0.46
52-week range
0.841 – 4.31
Day range
1.91 – 2.17
Volume / Avg
6.24M / 6.25M
Beta
—

52-week range

$0.841$4.31

NAUT stock today

On Nov 20, NAUT ended the session at $2.12, shedding $0.05 (2.30%), versus the S&P 500's 3.70% decline. At this level, NAUT sits in the middle of its 52-week range of $0.841 to $4.31: 50.8% below the high, set on Mar 25, 2026 and 152.1% above the low. NAUT is up 8.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.4%.

Nautilus Biotechnology has posted a net loss over the last twelve months (EPS of -$0.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Nautilus Biotechnology

Company profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. Sujal M. Patel
Headquarters
Seattle, WA
Employees
128
IPO year
2020

Financial highlights

Full financials

Nautilus Biotechnology reported a net loss of $59.0 million, compared with a loss of $70.8 million a year earlier. Diluted earnings per share came in at -$0.47.

Nautilus Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-59.00M$-70.78M$-63.67M$-57.92M$-50.31M
EPS (diluted)$-0.47$-0.56$-0.51$-0.46$-0.60

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$4.00+88.68%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$-0.11 vs $-0.14
Surprise
+21.43%

NAUT news

All NAUT news

Nautilus Biotechnology peers

Industrials sector
NAUT peer companies
CompanyPrice% ChgMarket capCompare
LABStandard BioTools Inc.0.631+2.82%$249.11Mvs NAUT
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs NAUT
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs NAUT
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs NAUT
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs NAUT
PACBPacific Biosciences of California Inc.1.63-7.39%$508.95Mvs NAUT
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs NAUT
EYPTEyePoint Inc.0.2342-11.36%$26.65Mvs NAUT

Indexes, lists and sector

Nautilus Biotechnology stock FAQ

What is Nautilus Biotechnology's stock price today?

NAUT last traded at $2.12 as of Nov 20, 4:00 PM EST, down 2.30% on the day. Prices are delayed at least 15 minutes.

Who is Nautilus Biotechnology's CEO?

Mr. Sujal M. Patel is the chief executive officer of Nautilus Biotechnology Inc., which has about 128 employees.

What is the NAUT 52-week high?

The 52-week high for NAUT is $4.31 and the 52-week low is $0.841. The stock is currently 50.8% below its high.

Compare NAUT